Literature DB >> 31466608

Current and Future Cell Therapy Standards and Guidelines.

J Wade Atkins1, Kamille West2, Kimberly A Kasow3.   

Abstract

Cell biology researchers, cellular engineers, and clinicians are teaming together to create powerful drugs. The use of cell-derived products as biologics is rapidly advancing. These human cell-based products have great potential for treating serious conditions but may have unidentified risks. Manipulations, expansions, and gene modifications increase the risks of unexpected outcomes. Implementation of the 21st Century Cures Act is opening avenues for accelerated approvals of these drugs for use in clinical trials and licensure. Although overwhelming, collaboration between regulators, industry, and research and medical communities enables the field to safely meet the needs of critically ill patients. Published by Elsevier Inc.

Entities:  

Keywords:  Biologic drug products; Cellular therapies; HCT/Ps; Licensure requirements; PHS 351 and 361

Mesh:

Substances:

Year:  2019        PMID: 31466608     DOI: 10.1016/j.hoc.2019.05.008

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  1 in total

1.  Green Synthesis of Highly Dispersed Zinc Oxide Nanoparticles Supported on Silica Gel Matrix by Daphne oleoides Extract and their Antibacterial Activity.

Authors:  Laleh Safavinia; Mohammad Reza Akhgar; Batool Tahamipour; Sayed Ali Ahmadi
Journal:  Iran J Biotechnol       Date:  2021-01-01       Impact factor: 1.671

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.